- Home
- STTK vs ELBM Comparison
STTK vs ELBM Comparison
Compare STTK & ELBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- ELBM
- Stock Information
- Founded
- STTK 2016
- ELBM 2011
- Country
- STTK United States
- ELBM Canada
- Employees
- STTK N/A
- ELBM N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- ELBM Industrial Machinery/Components
- Sector
- STTK Health Care
- ELBM Miscellaneous
- Exchange
- STTK Nasdaq
- ELBM Nasdaq
- Market Cap
- STTK 112.6M
- ELBM 97.4M
- IPO Year
- STTK 2020
- ELBM N/A
- Fundamental
- Price
- STTK $1.96
- ELBM $1.02
- Analyst Decision
- STTK Hold
- ELBM Strong Buy
- Analyst Count
- STTK 5
- ELBM 2
- Target Price
- STTK $3.00
- ELBM $2.20
- AVG Volume (30 Days)
- STTK 162.8K
- ELBM 10.9M
- Earning Date
- STTK 11-06-2025
- ELBM 11-14-2025
- Dividend Yield
- STTK N/A
- ELBM N/A
- EPS Growth
- STTK N/A
- ELBM N/A
- EPS
- STTK N/A
- ELBM N/A
- Revenue
- STTK $1,000,000.00
- ELBM N/A
- Revenue This Year
- STTK N/A
- ELBM N/A
- Revenue Next Year
- STTK N/A
- ELBM N/A
- P/E Ratio
- STTK N/A
- ELBM N/A
- Revenue Growth
- STTK N/A
- ELBM N/A
- 52 Week Low
- STTK $0.69
- ELBM $0.77
- 52 Week High
- STTK $2.71
- ELBM $8.70
- Technical
- Relative Strength Index (RSI)
- STTK 49.33
- ELBM 44.50
- Support Level
- STTK $1.86
- ELBM $0.97
- Resistance Level
- STTK $2.06
- ELBM $1.15
- Average True Range (ATR)
- STTK 0.14
- ELBM 0.14
- MACD
- STTK -0.00
- ELBM -0.06
- Stochastic Oscillator
- STTK 43.64
- ELBM 13.01
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.